Commercial Space Company Risk / Opportunity Ranking

Thesis: GalaxEye has the clearest opportunity evidence in the screen because it moved from pre-launch to an actual in-orbit milestone for Mission Drishti, described as the first OptoSAR satellite, and also has evidence of a commercialization path via an NSIL data-resale arrangement. For a 1 year+ horizon, a successful first satellite launch can support follow-on constellation buildout, data sales, and fundraising progression if commissioning and execution continue.

Why now: The key timing change is that earlier pre-launch coverage from April 23, 2026 was followed by launch coverage on May 3, 2026/May 4, 2026, and later June 16, 2026 context states the first satellite was launched in May 2026, confirming a business-state transition from concept/pre-launch to deployed asset status. The NSIL resale agreement was reported earlier on February 13, 2026, giving a potential go-to-market bridge once satellite data is available.

Caveats: Most reviewed sources rows are neutral facts or supporting article context rather than explicit positive evidence. Funding totals vary across articles (~$14.5M, $18.3M, ~$20M), so exact capitalization is uncertain

Thesis: Loft Orbital has the strongest opportunity case in this screen because multiple dated within the recent evidence window articles describe a multi-year CNES contract worth up to tens of millions of euros for a next-generation Earth observation constellation, with the first satellite scheduled for Q4 2026 or by year-end 2026. Additional 2026 context says Loft is expanding from hosted payloads into full-service 'constellations as a service,' which supports a durable 1 year+ strategic scaling thesis.

Why now: Why now is credible for a 1 year+ horizon because several dated articles from 2026 establish a recent contract win and near-forward deployment timeline: Loft announced on April 30, 2026 a multi-year CNES contract worth up to tens of millions of euros with first satellite scheduled to launch in Q4 2026. Via Satellite on May 1, 2026 described a 10-satellite EO constellation under that contract. SpaceNews on May 5, 2026 said Loft is expanding into 'full-service constellation deals'.

Caveats: Most retained support is supporting article context, which the reviewed sources treats as bounded context and weaker than direct dated event/fact evidence. Several favorable funding articles for Loft are dated January 2025 and were dropped by the 90-day recent evidence window, so they should not drive the current score. Execution risk remains around deploying the constellation and meeting the stated 2026 launch timing.

Thesis: Momentus has credible 1 year+ opportunity from recent execution milestones and commercial/government traction: Vigoride 7 launched in late March 2026, and in June 2026 the company announced a new commercial contract for Vigoride-9 in-orbit services. This supports product progression from demonstration toward revenue-bearing missions.

Why now: Why-now is supported by recent mission and contract evidence within the recent evidence window: on March 30, 2026 Momentus announced the successful launch of Vigoride 7 and called it its most advanced on-orbit demonstration campaign to date; on June 17, 2026 it announced a new commercial contract with LASP to host and operate the OWLS mission on Vigoride-9, expanding its commercial revenue portfolio.

Caveats: The SHIELD contract-vehicle selection is dated December 10, 2025 and outside the 90-day recent evidence window, so it is useful background but not a recency catalyst here. Some weak context rows repeat the same article-level claims and are not independent confirmation.

Thesis: Open Cosmos has the clearest visible operating-progress evidence in the screen. A June 17, 2026 article says it launched the first two satellites of its new Ka-band LEO telecom constellation and had secured a license from Liechtenstein a week earlier to use high-priority radio bands, indicating actual network rollout and regulatory progress toward sovereign and secure communications offerings for governments and enterprises.

Why now: The timing is favorable for a 1 year+ horizon because the latest dated evidence on June 17, 2026 indicates market entry and operation of the first telecom satellites, which can matter over a multi-quarter rollout period. A prior April 8, 2026 article also shows Open Cosmos spacecraft being used in the Orpheus UK military mission, adding defense-adjacent relevance. These dates are source dates extracted from the article summaries.

Caveats: Evidence is external article context and weak-context rows, not direct positive events. Same-article repeated rows are not independent confirmation.

Thesis: Rocket Lab has credible long-horizon opportunity from expanding beyond launch into higher-value national security satellite production and operations, while also showing continued commercial launch execution.

Why now: The main catalyst is the May 2026 award of Rocket Lab's first GEO satellite production program for the U.S. Space Force, which extends the company into a new orbital regime and broadens its mission model. That is paired with evidence of ongoing launch execution on May 22, 2026 through the ninth dedicated Electron mission for Synspective.

Caveats: The reviewed sources contain no direct negative events, so risk is mainly execution-based rather than explicitly evidenced adverse news. One representative item references stock performance but is undated and should not be treated as reliable recency proof.

Thesis: Sateliot has a solid 1 year+ opportunity setup because company-linked facts say it launched a €100 million Series C round to deploy 16 satellites for 5G IoT and direct-to-device connectivity, while later article context adds that it signed its first commercial contract for a dedicated LEO launch for two Tritó satellites in 2027. The combination of financing and launch planning supports constellation build-out potential.

Why now: The sequence matters: the company launched the Series C on April 8, 2026/April 13, 2026, then later reporting on May 21, 2026 noted a first commercial launch contract, and June 24, 2026 reporting still described the round as seeking capital and a lead investor. That mix creates both opportunity and financing risk over a 1 year+ horizon.

Caveats: The reviewed sources does not provide a direct positive event row for the first commercial contract; that support is supporting article context and weaker than a structured company event row. Later dated coverage indicates financing is still being sought, which partially offsets the opportunity thesis. Undated context items exist in the reviewed sources but are not used for recency-sensitive judgments.

Thesis: SatSure has the strongest non-Boeing opportunity setup in this screen because multiple recent article summaries indicate it secured a 246 million rupee ($2.57 million) grant from India's space regulator to develop AI-powered Earth observation models, and a later June 2026 article says Safran Electronics & Defense and SatSure signed an MoU to collaborate on GEOINT solutions for the Indian market. Together these suggest both public-sector support and ecosystem partnership momentum relevant over a 1 year+ horizon

Why now: Why now is strong because the June 11-22, 2026 evidence sequence shows fresh capital support first, then a later strategic partnership, suggesting opportunity maturation within weeks rather than stale background context

Caveats: Most evidence is supporting article context or weak context rather than direct positive events. Same-story repetition around the grant should not be treated as independent confirmation. No direct available evidence of revenue, backlog conversion, or deployment milestones.

Thesis: Starfish Space has the strongest positive evidence in the screen: recent Series B funding of more than $100 million and company-linked evidence of existing work with Space Force, NASA, and SES support a multi-year scaling thesis in on-orbit servicing.

Why now: The timing is favorable for a 1 year+ horizon because recent financing on April 7, 2026 was explicitly tied to executing first servicing missions and boosting production, following prior government contract momentum

Caveats: The strongest support is external web-search evidence, though it is company-linked and dated. Some contract details in weaker article context vary and should not be over-aggregated across repeated articles.

Thesis: TakeMe2Space has recent funding support from IN-SPACe under the Technology Adoption Fund, with the article stating selected startups will each receive up to ₹25 crore, which supports a durable financing-and-development opportunity over a 1 year+ horizon.

Why now: The IN-SPACe funding article is dated June 12, 2026, very recent within the recent evidence window, and describes first investment into selected Indian spacetech startups including TakeMe2Space, which could shape the next year of development. Source date: June 12, 2026

Caveats: Reviewed evidence notes prior broader membership support, but only one in-window article context is retained here. Evidence is supporting article context only despite stronger historical support counts.

Thesis: Turion Space has credible long-horizon opportunity because the reviewed sources show a sizable Series B closed on April 15, 2026 to accelerate deployment of its space domain awareness satellite fleet, alongside evidence that it has already launched spacecraft and is expanding a maneuverable satellite fleet for in-orbit observation missions.

Why now: The key timing driver is the dated financing round on April 15, 2026, which the reviewed sources say positions the company to scale beyond single-mission spacecraft toward a persistent SDA constellation, a development relevant over a 1 year+ horizon.

Caveats: The reviewed sources have no direct positive or negative dated events; the case relies on supporting article context rather than stronger internal company-specific events. The company website context on May 23, 2026 is weaker than independent company-specific event evidence and should not be overweighted. Citation

Thesis: Astrobase has visible funding support tied to a specific propulsion-development goal. A June 12, 2026 article says IN-SPACe selected it under the Technology Adoption Fund and that each project can receive up to ₹25 crore; the same summary says Astrobase aims to develop a high-thrust closed-cycle liquid rocket engine. For a 1 year+ horizon, non-dilutive or quasi-public funding for propulsion development is a meaningful opportunity signal.

Why now: The funding article is recent, with published June 12, 2026, and specifically notes this as IN-SPACe's first investment in Indian startups under the TAF scheme. That timing matters for a 1 year+ horizon because it may enable development progress over coming quarters.

Caveats: Visible evidence is only one external article summary despite the membership rationale referencing multiple structured support articles. No technical test results or customer contracts are provided in the exposed evidence.

Thesis: Blue Origin has meaningful long-horizon upside from multiple recent demand signals: a Space Force national security launch task order, a planned return-to-service New Glenn launch for 48 Amazon Leo satellites, and a NASA moon-base award tied to a fall 2026 target window.

Why now: The setup is active and recent: on May 30, 2026 SpaceNews reported Blue Origin received an NSSL task order hours before a New Glenn explosion, while on May 27, 2026 GeekWire reported New Glenn was preparing to return to service for an Amazon Leo mission after its first launch failure; on May 26, 2026 Investing.com summarized a NASA moon-base contract with launch no earlier than fall 2026

Caveats: Positive evidence is mostly supporting article context rather than direct events. One external article is undated and is not relied on for recency proof. Government support after the anomaly partially offsets, but does not erase, execution risk.

Thesis: ElevationSpace has one of the better opportunity setups in this screen because the reviewed sources includes a recent dated article saying it raised $40 million in Series B funding, bringing total raised to $63.5 million, for a business developing space-to-Earth transportation and a space environment utilization and recovery platform. A large recent financing can support product development and scaling over a 1 year+ horizon.

Why now: The catalyst is recent and dated: the financing article is timestamped June 19, 2026, which is inside the 90-day recent evidence window and recent enough to matter for a 1 year+ business-building horizon.

Caveats: Support is still supporting article context rather than direct positive events. Only one article is available, limiting corroboration.

Thesis: General Atomics has the clearest opportunity signal in the screen because an article dated April 8, 2026 says Space Systems Command awarded 14 companies more than $1.8 billion in Andromeda contracts for the Geosynchronous Reconnaissance & Surveillance Constellation, and General Atomics is named among the companies. For a 1 year+ horizon, inclusion in a large U.S. defense-space procurement could support durable program participation if it converts into funded work streams, though the reviewed sources only provides supporting article context rather than a direct company event row., April 8, 2026

Why now: The catalyst is recent within the reviewed sources recent evidence window: the is April 8, 2026, and it describes Space Force awarding Andromeda contracts, a potentially durable procurement cycle relevant to a 1 year+ horizon., April 8, 2026

Caveats: This is supporting article context/weak context, not a direct company event row. Same-article repeated rows in the reviewed sources are not independent confirmation.

Thesis: GITAI has the strongest opportunity setup in this screen because a dated June 16, 2026 company announcement says it completed the flight model of its S3 robotic satellite mission for an on-orbit servicing technology demonstration and framed the platform as supporting future defense-focused LEO constellation services, indicating tangible program maturation rather than just category membership.

Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year.

Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof.

Thesis: Intuitive Machines has moderate long-horizon opportunity because recent Space Force selection expands its relevance beyond lunar services into space surveillance capabilities, potentially broadening its addressable defense business.

Why now: The timing case comes from May 12, 2026 reporting that Intuitive Machines was selected for the Space Force Andromeda IDIQ to develop space surveillance capabilities through 2030 and beyond, described as the company's first major selection following the Lanteris Space acquisition.

Caveats: The reviewed sources provide supporting article context but no direct structured fact with quantified contract value specific to Intuitive Machines. No direct adverse evidence is available; risk is based on competitive award structure and evidence limitations. Long-horizon upside depends on conversion from selection status into meaningful programs.

Thesis: Kepler shows a meaningful operational milestone: the company said it successfully launched the first tranche of optical relay satellites and that a 10-satellite ring marks the beginning of its operational optical data relay network. For a 1 year+ horizon, first-network deployment can support follow-on service activation and adoption.

Why now: The latest visible evidence is dated June 23, 2026, making the milestone recent within the 90-day recent evidence window. The article explicitly frames this as the beginning of an operational network, which is more relevant to a 1 year+ horizon than a short-lived announcement.

Caveats: Primary evidence is from Kepler's own site. No direct contract, revenue, or financing detail is provided in the visible evidence. Same article appears in both representative and weak-context forms, which is not independent confirmation.

Thesis: L3Harris has a moderate opportunity case from current participation in the Space Force’s Andromeda space domain awareness effort, which could support multi-year defense-space positioning. Recent article context published April 8, 2026 lists L3Harris among the companies awarded Andromeda contracts for RG-XX satellites.

Why now: The recent timing anchor is the April 8, 2026 Andromeda article. Older 2020 MOSSAIC history exists in the reviewed sources but should not drive the current timing view because it is outside the recent evidence window and materially older than the current contract context.

Caveats: Current opportunity case depends on supporting article context rather than available direct positive events. The reviewed sources includes an older 2020 contract article, but that is not recent support for 'why now'.

Thesis: Recent supporting article context indicates Lockheed Martin won a Space Force contract worth up to $105 million to modernize the GPS ground control network and support GPS IIIF operations, which supports a durable government-space revenue opportunity over a 1 year+ horizon.

Why now: The relevant contract article is dated April 16, 2026, inside the 90-day recent evidence window, and describes current modernization work tied to GPS IIIF support, which can matter over a multi-quarter horizon. Source date: April 16, 2026

Caveats: Evidence is supporting article context only; no direct positive event row is available. Same article appears in multiple weak-context rows and does not count as independent confirmation.

Thesis: Among this screen, Logos has the clearest in-recent evidence window strategic progress: it recently secured FCC approval for a very large broadband constellation of up to 4,178 satellites, which is a meaningful regulatory milestone for a long-horizon satellite communications buildout.

Why now: A dated article within the 90-day recent evidence window, with based on April 13, 2026, states that Logos Space Services recently secured FCC approval for a constellation of up to 4,178 broadband satellites and described both target customers and technical architecture, making this a timely strategic-development signal for a 1 year+ horizon.

Caveats: Evidence is supporting article context, not a richer set of direct dated events/facts. Only one article after recent evidence window; same-article repeated rows are not independent confirmation.

Thesis: There is no usable in-window article or evidence detail in the reviewed sources to validate the company’s current operating status, financing trajectory, or any adverse development, so the main risk is evidence absence rather than proven business trouble.

Why now: There is no dated evidence retained after recent evidence window for Spacety in these reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency is uncertain.

Caveats: No representative articles or evidence are provided after recent evidence window. The only support is the phase2 membership rationale, which is weaker than direct event/fact evidence and does not provide /article summaries here. Because there is no in-window evidence, scores remain low on both axes.

Thesis: No direct negative evidence is present; the main issue is stale evidence and resulting uncertainty about current momentum or business state.

Why now: The only cited article is dated January 23, 2025, and the reviewed sources explicitly shows it was dropped by the 90-day recent evidence window cutoff of March 29, 2026.

Caveats: All dated evidence was excluded by recent evidence window. Do not use out-of-window article as current recency proof.

Thesis: Novel launcher and constellation buildout imply execution risk, but these reviewed sources provide no direct negative evidence within the recent evidence window.

Why now: Why-now is weak because the reviewed sources show 0 evidence kept after the 90-day recent evidence window, so recency cannot be established from local evidence.

Caveats: Phase2 membership rationale references and, but no article summaries or direct evidence are included, so they cannot be cited as factual support beyond noting the reviewed sources rationale. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Opportunity score kept low because positive thesis is not directly grounded in usable article evidence in these reviewed sources.

Thesis: Reviewed evidence risk is mainly lack of evidence visibility rather than documented negative developments. Without available direct evidence, current contract status, capex burden, and follow-on demand are unclear.

Why now: Why now is weak because no evidence survived into the ranking reviewed sources despite the membership rationale.

Caveats: Phase-2 membership rationale references: but no or direct evidence row is available here. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Do not infer opportunity from mission association alone without available evidence.

Thesis: Risk is mostly uncertainty risk because no kept recent evidence window evidence establish financing, contracts, milestones, or adverse developments.

Why now: Why now is weak because the reviewed sources' membership rationale references article describing an orbital power grid concept, but no article or reviewed evidence are provided for ranking use.

Caveats: No article is available for article. Coverage debug shows zero evidence after recent evidence window. Cannot elevate concept relevance into thesis attractiveness without direct business evidence.

Thesis: The same rationale suggests category ambiguity and execution risk: orbital AI/data-center activity may be conceptually ambitious, but the reviewed sources does not prove commercialization, deployment, or durable demand. No direct adverse evidence is available, so risk remains moderate and evidence-light rather than event-driven.

Why now: If the fundraising and product positioning are recent, they could support a multi-quarter buildout story, but the reviewed sources explicitly shows zero available evidence after recent evidence window, so recency and sequencing cannot be confirmed.

Caveats: Most supportive facts appear only in membership rationale, not available evidence. Reported funding cannot be treated as fully validated without direct article support in reviewed sources. No, quote, or dated direct summary is available.

Thesis: Risk remains modest because the reviewed sources offers no adverse evidence, but also no proof of contracts, funding, customer traction, or scaling milestones. That makes the opportunity early-stage and low-conviction.

Why now: The article is within the recent evidence window and dated May 25, 2026, but it is a company-site style description rather than an independently reported business event, so it supports relevance more than momentum

Caveats: Evidence is article-level company context, not a direct commercial milestone. No direct traction, financing, or contract evidence is provided. Same-article repeated rows are not independent confirmation.

Thesis: The reviewed sources contain no retained article/evidence detail after recent evidence window to confirm deliveries, customer adoption, financing, or execution setbacks, so business risk cannot be judged confidently.

Why now: There is no dated evidence retained after recent evidence window for SWISSto12. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so the timing case is not established from these reviewed sources.

Caveats: Assessment relies only on the reviewed sources' membership rationale, not direct quoted event/fact evidence with support. No representative articles are included despite article IDs being referenced in the rationale. Potential opportunity could be meaningful, but evidentiary support inside these reviewed sources is too thin for a stronger score.

Thesis: Risk scores slightly above minimal only because evidence absence is meaningful for ranking confidence and because the reviewed sources gives no current direct positive operating or contract evidence inside the recent evidence window. There is still no direct adverse event in the reviewed sources.

Why now: There is no valid near-term or long-horizon catalyst from the reviewed sources because coverage data shows zero evidence after recent evidence window; current state cannot be confirmed from local evidence.

Caveats: No evidence remained after the 90-day recent evidence window. The reviewed sources includes only sparse membership rationale, not current direct evidence.

Thesis: Main risk is evidence thinness and uncertain recency: the reviewed sources contain no direct negative evidence, but the only business evidence is undated supporting article context, so current contract status and execution progress are uncertain.

Why now: Why now is weak: the only cited catalyst is an undated article stating the company won an ESA cargo contract, and the reviewed sources provide no newer dated confirmation within the 90-day window. Recency-sensitive conclusions should therefore be cautious.

Caveats: Only undated article-context evidence is present; no direct structured positive event/facts survived. The reviewed sources includes no within the recent evidence window dated follow-up on financing, program execution, or milestone delivery. Article-level context is weaker than direct company event/fact evidence.

Thesis: Risk remains moderate because the reviewed sources provide no direct available evidence after recent evidence window to confirm award economics, schedule, or follow-on conversion.

Why now: Government program selection could matter over 1 year+, but the reviewed sources does not provide surviving evidence with timing details after recent evidence window.

Caveats: No -bearing direct evidence row is available for the referenced Andromeda selection article. Selection does not prove revenue realization or contract scale.

Thesis: The main risk in these reviewed sources is evidentiary rather than business-specific: there is no direct negative evidence, but also no direct structured positive event row such as a contract, financing, or milestone within the recent evidence window. Opportunity therefore rests on supporting article context rather than stronger company-specific event evidence.

Why now: The most recent dated context is June 22, 2026, which is within the 90-day recent evidence window and indicates Umbra currently operates a SAR constellation and serves government and commercial customers. However, no nearer-term catalyst row is available, so the timing case is moderate rather than strong.

Caveats: Evidence is supporting article context/weak context only, not a direct structured positive event row. The July 31, 2024 Umbra article is outside the 90-day dated recent evidence window and was dropped for recency-sensitive scoring.

Thesis: No material adverse evidence is available, so there is no supported negative thesis from these reviewed sources alone.

Why now: The membership rationale cites articles: and: but no article summaries or evidence are available after recent evidence filtering for ranking.

Caveats: Launch-industry membership is not itself a directional thesis. Coverage debug shows zero evidence after recent evidence window despite many considered articles. No direct contract, launch cadence, backlog, or failure evidence is available in these reviewed sources.

Thesis: Risk remains moderate because the reviewed sources provide only weak supporting article context rather than direct structured company events, limiting confidence in scope, economics, and timing of impact.

Why now: Recent context exists within the recent evidence window: is dated June 11, 2026 and states Viasat was among operators selected under a combined $437.7 million award and has a defined supplier stack for its PTS-G satellite, which could matter over a 1 year+ horizon. Source date basis is source date.

Caveats: This is supporting article context only; the reviewed sources classifies it under weak context, so it is weaker than direct event/fact evidence. Same article appears in two weak-context rows and should not be treated as independent confirmation. An older Viasat company-hosted article exists but is outside recent evidence window, February 29, 2024

Thesis: A mild risk prior exists only from uncertainty: despite many articles considered, no retained evidence remains after recent evidence window, so no current adverse thesis is established and business-state recency is unclear.

Why now: There is no citable within the recent evidence window evidence in the reviewed sources to justify a strong 1 year+ 'why now' despite broad historical article coverage.

Caveats: Phase-2 rationale references: and: but no or summaries are provided here. Coverage debug shows 78 articles considered but 0 article IDs after recent evidence window and 0 available evidence. Ticker ambiguity exists in aliases (VOYG, VYGR), but the required output ticker is VOYG.

Thesis: The same rationale implies adjacency rather than a clearly established core space operator role, creating execution and relevance risk, but no material adverse event evidence is available after recent evidence filtering.

Why now: No reviewed sources-grounded timing support is available for why this matters now over a 1 year+ horizon; the reviewed sources retains zero evidence after the cutoff and provides no citable for article.

Caveats: Reviewed evidence is limited to a membership rationale; there are no representative article summaries, or evidence after recent evidence window. The cited article id is not accompanied by a in the reviewed sources, so it cannot be used for factual claim citation. Slightly higher opportunity/risk than some peers reflects adjacency language in the reviewed sources rationale only, not strong direct evidence.

Thesis: No direct negative evidence is present; the practical risk to ranking is simply insufficient current evidence.

Why now: The reviewed sources includes no representative article or retained evidence within the 90-day recent evidence window, so recency and current status are uncertain for Xdlinx in this screen.

Caveats: No retained evidence after recent evidence window. Phase-2 membership support alone is not enough for a stronger score.

Thesis: Risk is modestly elevated versus some peers because the company appears only once in the reviewed sources, and the lack of retained recent evidence means the claimed business standing cannot be validated or updated within the recent evidence window.

Why now: No current catalyst is evidenced; coverage after recent evidence window is empty.

Caveats: Reviewed evidence mentions: but provides no. Higher-revenue claim is only from membership rationale and may not be current. No retained structured positive or negative evidence after recent evidence window.

Thesis: Risk is mainly execution and proof-of-delivery risk because the surviving evidence is undated company context without dated commercial milestones, customers, or financing in the reviewed sources.

Why now: Why now is weak: the only surviving evidence is undated, so recency-sensitive claims are uncertain

Caveats: Evidence is undated and should not be treated as recency proof. No direct positive event or traction evidence is available. Opportunity case is strategic but low-conviction.

Thesis: No material adverse evidence is available within the reviewed sources' recent evidence window. Risk remains low-scored due to lack of evidence rather than demonstrated safety.

Why now: There is no usable within the recent evidence window evidence in the reviewed sources; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for ADAspace.

Caveats: Phase-2 membership rationale references article: but the reviewed sources provide no for citation. No direct positive or negative evidence survived the 90-day recent evidence window.